Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause

Inclusion Criteria:

• Good general health as determined through a review of their medical history andafter conducting a general physical examination

• Body weight ≥ 45 to ≤ 120 kg

• Body mass index (BMI) between 18.5 kg/m2 and 35.0 kg/m2

• Non- or ex-smoker (an ex-smoker is defined as someone who completely stopped usingnicotine products for at least 90 days prior to the first study drug administration)

• Healthy man or a postmenopausal woman who is ≥ 40 and ≤ 75 years of age OR apostmenopausal woman with or without VMS and who is ≥ 40 and ≤ 75 years of age OR apostmenopausal woman who is ≥ 40 and ≤ 75 years of age seeking treatment for relieffor VMS

• If a woman:

1. has been compliant with local and/or national guidelines for breast cancerscreening with documentation of a mammogram with normal/negative or noclinically significant findings. A screening mammogram may be conducted duringstudy screening period, if needed

2. has spontaneous amenorrhea for at least 12 consecutive months; or spontaneousamenorrhea for at least 6 months with biochemical criteria of menopause (follicle-stimulating hormone [FSH] > 40 IU/L); or had a bilateral oophorectomy > 6 weeks prior to screening, or s/p hysterectomy at least 6 weeks prior toscreening and meeting the biochemical criteria of menopause (FSH > 40 IU/L)

• If a man:

1. possess a testosterone concentration of ≥ 15 nmol/L at the time of screening

2. can procreate and agree to use one of the acceptable contraceptive regimens andnot to donate sperm from the first study drug administration to at least 90days after the last drug administration OR is unable to procreate; defined assurgically sterile

Exclusion Criteria:

• Pregnancy and/or lactation.

• Has endometrial hyperplasia or history of abnormal uterine bleeding without anidentified cause in the past 6 months

• Previous or current history of a malignant tumor, except for non-melanoma skincancer.

• Seated pulse rate less than 50 beats per minute (bpm) or more than 100 bpm or aseated blood pressure < 90/50 mmHg or > 140/90 mmHg

• eGFR < 60 mL/min/1.73 m2

• Severe hypersensitivity reactions (like angioedema) to any drugs.

• Significant uncontrolled cardiovascular, pulmonary, gastrointestinal, hepatic,renal, hematologic, neurological, psychiatric, endocrine, immunologic, ordermatologic disease.

• Clinically significant ECG abnormalities

• Presence or history of cardiogenic syncope in the past 6 months.

• Use of any over-the-counter products (including supplements) containing testosteroneor any medication (hormonal, prescription, over the counter, herbal, or natural) forthe treatment of hot flashes during the screening period and throughout the study;must be discontinued at least 28 days prior to study drug administration

• Employees of the sponsor or the investigator site and other individuals who aredirectly involved in the conduct of the study